Иммунные и метаболические взаимосвязи псориаза с коморбидными состояниями

В обзоре представлены новые данные коморбидных ассоциаций псориаза с метаболическим синдромом, сердечно-сосудистыми заболеваниями, дисбиозом кишечника и другой патологией.

Анализ литературных данных показал, что псориаз необходимо рассматривать как системное воспалительное состояние, лежащее в основе коморбидных ассоциаций. Патогенез метаболических нарушений при псориазе связан с конституционально детерминированными иммунными гиперреактивностями. В свою очередь развившиеся метаболические отклонения усиливают иммунное воспаление за счет вновь образованных молекулярных образов опасностей (DAMP). Перспективным в понимании причин формирования коморбидных состояний и заболеваний при псориазе является изучение общих показателей обмена веществ, что позволит расширить представления о механизмах формирования коморбидности при псориазе.

1. Аминокислоты крови в патогенезе и клинике ишемической болезни / М.С. Синькеев, Ю.И. Скворцов, Т.М. Богданова, К.Ю. Скворцов // Международный журнал прикладных и фундаментальных исследований. – 2014. – № 11(3). – С. 480-484.

2. Орлов Е.В. Оценка метаболического статуса и клеточного состава крови при псориазе и псориатическом артрите / Е.В. Орлов, М.С. Арнаутова, Н.И. Гергель // Медицинский альманах. – 2013. – №5 (29). – С.197-200.

3. Псориаз у пациентов с метаболическим синдромом: клинические аспекты проблемы / С.Г.Лыкова, М.А. Моржанаева, О.Б. Немчанинова, Е.В. Свечникова // Клиническая дерматология и венерология. – 2020. – №19(2). – Р. 214- 222. – DOI: 10.17116/klinderma202019021214.

4. Скворцов Ю. И. Гомоцистеин как фактор риска развития ИБС (обзор)/ Ю.И Скворцов, А. С. Королькова // Саратовский науч.-медицин. журнал. – 2011. – Т. 7. – № 3. – С. 619-624.

5. A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis / O. Awosika, M. G. Eleryan, M. Rengifo-Pardo [et al] // Journal of Clinical and Aesthetic Dermatology. – 2018. – No. 11(6). – P. 33-37.

6. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis / A.W. Armstrong, S.V. Voyles, E.J. Armstrong [et al] // Exp Dermatol. – 2011. – Jul. 20(7). – P. 544-9. – Doi: 10.1111/j.1600-0625.2011.01308.x.

7. Advances in understanding the immunological pathways in psoriasis / S.R. Georgescu, M. Tampa, C. Caruntu [et al] // International Journal of Molecular Sciences.– 2019. – № 20. – Р. 739. – Doi: 10.3390/ijms20030739.

8. Alterations in plasma lipid profile and cardiovascular risk indicators in clinically subgrouped psoriasis / S. Srinivas, S. Nagendra, P. Goudappala, R.T. Kashinath // International Journal of Research in Dermatology. – 2019. – V.5. – №2. – Р. 2455-4529.

9. Apolipoprotein E gene polymorphism and serum lipid profile in Saudi patients with psoriasis / F. Al Harthi, G.B. Huraib, A. Zouman [et al] // Disease Markers. – 2014. – 239645. – Doi: 10.1155/2014/239645.

10. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation/ E. Smith, K. M. Prasad, M. Butcher [et al]. – Text : electronic // Free PMC article. – 2010. – 20. – 121(15). – Р. 1746-55. – Doi: 10.1161/CIRCULATIONAHA.109.924886.

11. Boehncke, W.H. Psoriasis / W.H. Boehncke, M.P. Schön // Lancet. – 2015. – № 386. – Р. 983-994. – DOI: 10.1016/S0140-6736(14)61909-7.

12. Can microbiology afect psychiatry? A link between gut microbiota and psychiatric disorders / E. Gulas, G. Wysiadecki, D. Strzelecki, [et al] // Psychiatria Polska. – 2018. – 52. – Р. 1023-1039.

13. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia / S.E. Choon, N.M. Lai, N.A. Mohammad [et al] // International Journal of Dermatology. – 2014. – 53. – 676–684. – Doi: 10.1111/ijd.12070.

14. Current developments in the immunology of psoriasis / F. Grän, A. Kerstan, E. Serfling [et al] // Yale Journal of Biology and Medicine. – 2020. – № 93. – Р. 97–110.

15. Domagała, A. Antihistamines in the treatment of pruritus in psoriasis / A. Domagała, J. Szepietowski, A. Reich. – Text : electronic // Advances in Dermatology and Allergology. – 2017. – № 5. – Р. 457-463. – DOI: 10.5114/ada.2017.71112.

16. Dysbiosis of gut microbiota was closely associated with psoriasis / L. Huang, R. Gao, N. Yu [et al] // Sci China Life Sci. –2018. – 62(6). – Р. 807-815 https://doi.org/10.1007/s11427-018-9376-6.

17. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability / C. Erbel, T.J. Dengler, S. Wangler [et al] // Basic Res Cardiol. – 2011. –№106 (1). – Р.125-134. – Doi: 10.1007/s00395-010-0135-y.

18. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention / Younossi Z, Anstee QM, Marietti M, [et al] // Nature Reviews Gastroenterology & Hepatology. – 2018. – 15(1):11-20. – Doi: 10.1038/nrgastro.2017.109.

19. Guidelines on the treatment of psoriasis vulgaris (English version). Update / A. Nast, W.H. Boehncke, U. Mrowietz [et al] // J Dtsch Dermatol Ges. – 2012. – 10(2). – Р. 1-95. – Doi: 10.1111/j.1610-0387.2012.07919.x.

20. Gut microbial composition in patients with psoriasis / F.M. Codoñer, A. Ramírez-Bosca, E. Climent [et al] // Scientific Reports. – 2018. – 3812. – Doi: 10.1038/s41598-018-22125-y.

21. Gut microbiota dysbiosis in a cohort of patients with psoriasis / C. Hidalgo-Cantabrana, J. Gómez, S. Delgado [et al] // British Journal of Dermatology. – 2019. – 181(6). –Р. 1287-1295. – Doi: 10.1111/bjd.17931. https://doi.org/10.1111/bjd.17931.

22. Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study / A.M. Tobin, R. Hughes, T. Leong [et al] // Clin. Exp. Dermatol. – 2011. – Vol. 36. – Issue 1. – P. 19-23.

23. Hypertension and risk of psoriasis incidence: an 11-year nationwide population-based cohort study / H.N. Kim, K. Han, S.W. Song, J.H. Lee // PLoS ONE. – 2018. – e0202854. – Doi: 10.1371/journal.pone.0202854.

24. Intestinal microbiota profling and predicted metabolic dysregulation in psoriasis patients / Y.-J. Chen, Hsiu Ho, Ching-Hung Tseng [et al]. – Text : electronic // Experimental Dermatology. – 2018. – 27(12). – Р. 1336-1343. – DOI:10.1111/exd.13786.

25. Jensen, P. Psoriasis and obesity / P. Jensen, L. Skov // Dermatology. – 2016. – 232. – 633- 639. – Doi: 10.1159/000455840.

26. Leptin and the Skin: A New Frontier / B. Poeggeler, C. Schulz, M.A. Pappolla. [et al] // Experimental Dermatology. – 2010. – Vol. 19. – No. 1. – Р. 12-18. – Doi:10.1111/j.1600-0625.2009.00930.x.

27. Markers of systemic infammation in psoriasis: a systematic review and meta-analysis / E.A. Dowlatshahi, E.A. van der Voort, L.R. Arends, T. Nijsten // British Journal of Dermatology. – 2013. – 169. – 266–282. – Doi: 10.1111/bjd.12355.

28. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity / G. Musso, R. Gambino, M. Cassader, G. Pagano // Annals of Medicine. – 2011. – №43(8). – 617-49. – Doi: 10.3109/07853890.2010.518623.

29. Metabolic syndrome in patients with psoriasis / A. Wolska, M. Michalsk-Jakabus, A. Pietrzak [et al] // Polski Merkuriusz Lekarski. – 2014. – 36 (213). – Р. 215-219.

30. Methylenetetrahydrofolate Reductase C677T Gene Polymorphism as Risk Factor for Psoriasis in Saudis / G.B. Huraib, F.A. Harthi, M. Arfin [et al] // Biomark Insights. – 2019. – V. 14. – P. 1-5. – Doi: 10.1177/1177271919830973.

31. Mylonas, A. Psoriasis: Classical vs. paradoxical. Te Yin-Yang of TNF and type I interferon / A. Mylonas, C. Conrad // Front. Immunol. – 2019. – № 9. – Р. 2746.

32. NAFLD and liver transplantation: Current burden and expected challenges / R. Pais, A. S. 4th Barritt, Y. Calmus [et al] // Journal of Hepatology – 2016. – 65(6). – 1245-1257. – Doi: 10.1016/j.jhep.2016.07.033.

33. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation / A. Johnston, S. Arnadottir, J.E. Gudjonsson [et al] // British Journal of Dermatology. – 2008. – 159(2). – Р. 342-50. – Doi: 10.1111/j.1365-2133.2008.08655.x.

34. Obesity, waist circumference, weight change, and risk of incident psoriasis: prospective data from the HUNT study / I. Snekvik, C. H. Smith, TIL. Nilsen [et al] // Journal of Investigative Dermatology. – 2017. – 137. – 2484-2490. – Doi: 10.1016/j.jid.2017.07.822.

35. Overweight and weight gain predict psoriasis development in a population-based cohort / K. Danielsen, T. Wilsgaard, A.O. Olsen, A.S. Furberg // Acta Dermato-Venereologica. – 2017. – 97(3). – 332-339. – DOI: 10.2340/00015555-2530.

36. Pathogenesis of chronic plaque psoriasis and its intersection with cardiometabolic comor bidities / P. Gisondi, F. Bellinato, G. Girolomoni, C. Albanesi // Front. Pharmacol. – 2020. – Р. 11-117. – Doi: 10.3389/fphar.2020.00117.

37. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease / R. Abedini, M. Salehi, V.Lajevardi, S. Beygi // Clinical and Experimental Dermatology. – 2015. – № 40. – Р. 722-727. – Doi: 10.1111/ced.12672.

38. Prevalence of metabolic syndrome in patients with psoriasis. / I. Zindancı, O. Albayrak, M. Kavala [et al] // Scientific World Journal. – 2012. – 2012:312463. – Doi: 10.1100/2012/312463.

39. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics./ P.J. Mease, D.D. Gladman, K.A. Papp [et al] // Journal of the American Academy of Dermatology. – 2013. – № 69. – Р. 729-735.

40. Psoriasis and comorbid diseases: Implications for management / J. Takeshita, S. Grewal, S.M. Langan [et al] // Journal of the American Academy of Dermatology. – 2017. – 76. – 393- 403. – Doi: 10.1016/j.jaad.2016.07.065.

41. Psoriasis and the risk of diabetes: a prospective populationbased cohort study / M.T. Wan, D.B. Shin, R.A. Hubbard [et al] // Journal of the American Academy of Dermatology. – 2018. – 78. – 315–322. – Doi: 10.1016/j.jaad.2017.10.050.

42. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study / O. Ahlehoff, G.H. Gislason, J. Lindhardsen [et al] // PLoS ONE. – 2011. – 6. – e18125. – Doi: 10.1371/journal.pone.0018125.

43. Psoriasis is associated with a greater risk for cardiovascular procedure and surgery in patients with hypertension: A nationwide cohort study / H.Y. Chiu, W. L. Chang, M.N. Shiu [et al] // J Dermatol. – 2018. – 45(12). – 1381-1388. – Doi: 10.1111/1346-8138.14654.

44. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study / H. Yeung, J. Takeshita, N.N. Mehta [et al] // JAMA Dermatology. – 2013. – 149(10). – 1173- 9. – Doi: 10.1001/jamadermatol.2013.5015.

45. Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background / G. Ganzetti, A. Campanati, E. Molinelli, A. Offidani // World J Cardiol. – 2016. – 8(2). – 120-31. – Doi: 10.4330/wjc.v8.i2.120.

46. Psoriasis: A mixed autoimmune and autoinfammatory disease / Y. Liang, M. K. Sarkar, L.C. Tsoi, J. E Gudjonsson // Curr. Opin. Immunol. – 2017. – № 49. – Р. 1-8.

47. Psoriatic disease is associated with systemic inflammation, endothelial activation, and altered haemostatic function / M.J.E. Visser, C. Venter, T J. Roberts [et al] // Scientific Reports. – 2021. – № 11. – 13043. – Doi: 10.1038/s41598-021-90684-8.

48. Psoriatic lesions are characterized by higher bacterial load and imbalance between Cutibacterium and Corynebacterium / C. Quan, X.Y. Chen, X. Li [et al] // Journal of the American Academy of Dermatology. – 2020. – 82(4). – Р. 955-961. – Doi: 10.1016/j.jaad.2019.06.024.

49. Quality of life and comorbidities in palmoplantar pustulosis—a cross-sectional study on 102 patients/ H. Trattner, S. Blüml, I. Steiner [et al].// Journal of the European Academy of Dermatology and Venereology. – 2017. – 31. – 1681- 1685. – Doi: 10.1111/jdv.14187.

50. Relationship between psoriasis and non-alcoholic fatty liver disease: Updated systematic review and adjusted meta-analysis / K. Phan, J. Onggo, O. Charlton, S. D. Smith // Australasian Journal of Dermatolog. – 2019. – 60. – e352–e355.

51. Serum Leptin, Resistin, and Adiponectin Concentrations in Psoriasis: A Meta-Analysis of Observational Studies / A. Kyriakou, A. Patsatsi, D. Sotiriadis, D.G. Goulis // Dermatology. – 2017. – 233(5). – Р. 378-389. – Doi: 10.1159/000481882.

52. Serum sphingolipid level in psoriatic patients with obesity / D. Kozłowska, E. Harasim-Symbor, H. Myśliwiec [et al] // Postȩpy Dermatologii i Alergologii. – 2019. – 36. – 714–721. Doi: 10.5114/ada.2019.91422.

53. Tcell hierarchy in the pathogenesis of psoriasis and associated cardiovascular comorbidities / F. Casciano, P.D. Pigatto, P.Secchiero [et al] // Front Immunol. – 2018. – № 9. – Р. 1390. – DOI: 10.3389/fimmu.2018.01390.

54. Te human microbiota and obesity: a literature systematic review of in vivo models and technical approaches / L. Carrera-Quintanar, D. Ortuño-Sahagún, N.N. Franco-Arroyo [et al] // International Journal of Molecular Sciences. – 2018. – 19. – 3827.

55. Terole of the microbiome in gut and joint infammation in psoriatic arthritis and spondyloarthritis / E. Gilis, C. Mortier, K. Venken [et al] // Journal of Rheumatology Supplement. – 2018. – 94. – Р. 36-39.

56. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. / M.A. Lowes, C.B. Russell, D.A. Martin [et al] //Trends Immunol. – 2013. – № 34(4). – Р. 174-81. – Doi: 10.1016/j.it.2012.11.005.

57. Thyroid dysfunction in patients with psoriasis: higher prevalence of thyroid dysfunction in patients with generalized pustular psoriasis / K. Namiki, M. Kamata, T. Shimizu [et al] // J. Dermatol. – 2020. – 47. – 133–139. – Doi: 10.1111/1346-8138.15178.

58. Trends in incidence of adult-onset psoriasis over three decades: a population-based study / M. Icen, C.S. Crowson, M.T. McEvoy [et al] // J Am Acad Dermatol. – 2009. – 60(3). – 394-401. – Doi: 10.1016/j.jaad.2008.10.062.

59. Wenk, K.S. Psoriasis and non-alcoholic fatty liver disease / K.S. Wenk, K.C. Arrington, A. Ehrlich // Journal of the European Academy of Dermatology and Venereology. – 2011. – 25. – Р. 383- 391. – DOI:10.1111/j.1468-3083.2010.03841.x.